BioSpace News Archive

Seattle Genetics Announces TUKYSA ® (tucatinib) Approved Within Months for All Countries Participating in FDA’s Project Orbis Initiative - Australia Joins U.S., Switzerland, Canada and Singapore in Approval of TUKYSA for the Treatment of Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer -

Halberd Corp. (OTC PINK:HALB) today announced the addition of Edson Brito to the Scientific Advisory Board. Mr. Brito is CEO and Chief Business Development Officer of Cellybri Advanced Therapies in Brazil.

- Final Clinical Results of a Phase 2b Study i n Alzheimer’s Disease with Lead Drug Candidate, PTI-125, Expected to be Announced September 2020 - - SavaDx Demonstrates Direct Evidence of Target Engagement & Treatment Effects - - Open-label Study Of PTI-125 Reaches >50% Enrollment - AUSTIN, Texas, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results f

Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today reported financial results for the quarter ended June 30, 2020. Second Quarter and Recent Business Updates On April 30, 2020, the Company announced that its registrational clinical trial, TBI-001, was published on April 29, 2020 in Neuromodulation: Technology at the Neural Interface . The TBI-

Inspire Medical Systems, Inc., announced that the Australian Therapeutic Goods Administration has approved Inspire therapy to treat moderate to severe OSA in patients who are unable to benefit from continuous positive airway pressure.

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET Corporate and Regulatory Highlights: Received Day-74 Letter for KP415 NDA; FDA has set PDUFA date of March 2, 2021 Announced that Corium, Inc., a portfolio company of GPC, will lead all commercialization activities for KP415 Announced issuance of two additional U.S. patents governing KP415 and KP484 Financial Highlights Reported Q2 2020 revenue of $6.9 million, including $5 million m

Total Revenue for Q2 2020 was approximately $1.2 million dollars Balance sheet strengthened significantly with $6.1 million cash raised in Q2 2020 Strategic co-promotion partnership with Menarini Silicon Biosystems to market and sell Menarini’s COVID-19 related products Conference call to be held at 4:30 p.m. Eastern Time today GAITHERSBURG, Md., Aug. 12, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular di

ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, today announced that it will host a conference call and live webcast on Tuesday, August 18, 2020

IMV Inc. (the “Company” or “IMV”) (TSX: IMV; NASDAQ: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced financial results for the second quarter ended June 30, 2020

Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR), the global leader in MRI-guided cardiac ablation products, is pleased to announce a sales collaboration with Optoacoustics Ltd, the world leader in innovative, high performance optical communication solutions for magnetic resonance (MR) applications.